Kolltan Pharmaceuticals Appoints Ronald A. Peck, M.D., Chief Medical Officer and SVP, Clinical Development

-New Executive Brings Substantial Track Record in Oncology and Novel Immuno-Oncology Drug Development and Commercialization

-Carolyn Sidor, M.D., Continues as an Advisor to the Company

NEW HAVEN, Conn.--()--Kolltan Pharmaceuticals, Inc. (“Kolltan” or the “Company”), a privately held clinical-stage company focused on the discovery and development of novel, best-in-class antibody-based drugs targeting receptor tyrosine kinases for the treatment of cancer and other diseases, today announced the appointment of Ronald A. Peck, M.D., as Chief Medical Officer and Senior Vice President, Clinical Development. Dr. Peck will lead the clinical development of Kolltan’s product pipeline and will report to President and Chief Executive Officer Gerald McMahon, Ph.D. Kolltan’s most advanced product candidates include KTN3379, which is in Phase 1b clinical trials, and KTN0158, which is anticipated to enter clinical trials in early 2016. Dr. Peck will succeed Carolyn F. Sidor, M.D., who will continue as a medical and regulatory consultant to the Company.

“Dr. Peck’s exceptional track record and experience in oncology clinical development and his accomplishments in immuno-oncology will contribute to the evaluation of our antibody therapeutics in oncology and other immune-related disorders.”

“We are pleased to welcome Ron to the Kolltan team as we are advancing KTN3379 in multiple clinical trials and progressing KTN0158 into clinical development,” stated Dr. McMahon. “Dr. Peck’s exceptional track record and experience in oncology clinical development and his accomplishments in immuno-oncology will contribute to the evaluation of our antibody therapeutics in oncology and other immune-related disorders.” Dr. McMahon added, “We greatly appreciate Carolyn’s hard work, mentorship, and clinical leadership over the past two years as she led the execution of our clinical development strategies. Furthermore, we appreciate her continued role to augment the team’s capabilities.”

Dr. Peck has over 15 years of extensive drug development expertise in oncology and other areas. Prior to joining Kolltan, Dr. Peck held roles of increasing responsibility at Bristol-Myers Squibb Company (“BMS”) since 2000, where he contributed to the successful development of multiple therapeutic drug products. Notably, Dr. Peck led the clinical development program for IXEMPRA® (ixabepilone), and he served most recently as Vice President, Global Development Lead for YERVOY® (ipilimumab), playing a key role in the approval and commercialization of this drug in all indications. Prior to his successful term at BMS, Dr. Peck was on the faculty at the University of Virginia in the division of hematology/oncology. Dr. Peck received his medical degree from Thomas Jefferson University and completed his residency in internal medicine and a fellowship in hematology and oncology at the Vincent Lombardi Cancer Center at Georgetown University, where he also went on to pursue a fellowship in Developmental Therapeutics. He is board-certified in medical oncology.

“I am very excited to join the Kolltan senior management team at this important time in the development of the Company. I look forward to working with the team in advancing the Company’s portfolio of innovative product candidates and bringing important new medicines to patients,” stated Dr. Peck.

About KTN3379

KTN3379 is a human monoclonal antibody designed to block the activity of ErbB3 (HER3), a receptor tyrosine kinase (RTK) that belongs to the epidermal growth factor receptor, or EGFR, family. ErbB3 is believed to be an important receptor regulating cancer cell growth and survival. ErbB3 is expressed in many cancers, including head and neck, thyroid, breast, lung, gastric, and melanoma. While there are several successful currently marketed products targeting two members of the EGFR family, there are none that directly target ErbB3. In cancer, ErbB3 activation can be driven by its ligand, neuregulin (NRG), or in its absence, through overexpression of its co-receptor ErbB2 (HER2).

About KTN0158

KTN0158 is a proprietary humanized monoclonal antibody designed using structure-based approaches to block the activation of KIT, an RTK that is expressed in many cancers and plays an important role in regulating mast cells. While there are several successful, currently marketed small molecule products targeting KIT, there are no therapeutic antibodies targeting KIT on the market. KIT has been demonstrated to play a role in the progression of several tumor types and may contribute to immune evasion of tumors. Further, KIT signaling regulates the activation of mast cells, immune cells involved in the onset and progression of inflammatory diseases such as neurofibromatosis type 1, allergy, and asthma.

About Kolltan Pharmaceuticals

Kolltan, a privately held clinical-stage company, is focused on the discovery and development of novel, best-in-class antibody-based drugs targeting receptor tyrosine kinases for the treatment of cancer and other diseases with significant unmet need. Kolltan’s founders and members of its management team have deep expertise and a proven track record in drug discovery, development, and commercialization of innovative therapeutics, including drugs targeting kinases. Kolltan is working in close collaboration with the laboratory of Kolltan Co-Founder, Dr. Joseph Schlessinger, as well as the Yale University medical and scientific community. The Company has a broad and novel portfolio of therapeutic biologics targeting multiple receptor tyrosine kinases that are advancing in clinical and preclinical development and are progressing toward potential achievement of multiple near-term milestones.

IXEMPRA® and YERVOY® are registered trademarks of Bristol-Myers Squibb Company.

Contacts

Media Inquiries:
Burns McClellan
Justin Jackson, 212-213-0006
jjackson@burnsmc.com
or
Investor Inquiries:
Kolltan Pharmaceuticals, Inc.
203-907-0938